Kopran Ltd
Kopran Ltd (KOPRAN)

Kopran Ltd (KOPRAN)

₹158.192.92%

Key Stats

₹154.4
Day's Price Range
₹161.7
₹153
52-Week Price Range
₹370.45
1 Month Return-16.08 %
3 Month Return-22.81 %
1 Year Return-24.46 %

Company Financials

  • Quarterly
  • Annual
Value in ₹ crore

Peer Comparsion

PE
Rank 81
11.09
EPS
Rank 121
₹13.84
BVPS
Rank 153
₹88.4
Dividend Yield
Rank 23
2.86%
ROE
Rank 377
3.75%
Price To Book Ratio
Rank 101
1.73
Debt To Asset
Rank 173
0.44

Company Information

Kopran was promoted by the Somani group and is controlled by Parijat Enterprises. The company came out with a public issue at a premium in Nov.92 to finance its backward integration project to produce drug intermediates for semisynthetic drugs and also to expand its antibiotic facility.Kopran manufactures pharmaceutical finished dosage forms and bulk drugs and distributes electronic equipment. It manufactures semisynthetic penicillin and is among the worlds highest producers in amoxycillin. Kopran also makes penicillinG acylase an enzyme made through fermentation. It has technical collaborations with Gesellschaft Fur Biotechnologische Germany Yuhan Corporation South Korea Ciba Corning Diagnostic US and Adac Laboratories US.Koprans bulk drug plant has been approved by the US FDA and the UK regulatory authorities. In 1995 the company was awarded the Quality Excellence award by the Indian Drug Manufacturers Association. Koprans high growth rate in exports has been recognised by a number of awards from CHEMEXCIL and the Ministry of Commerce.The company launched new products like AZ1 Caps Klodip Tabs Moclox Kid Tabs Amyn Kid Tabs TiniNF Amyn Caps and Amyn Dry Syrup. Kopran entered into a joint venture with M/s Industrial Promotion Services Ltd to take over a running unit viz Kampala Pharmaceuticals Industries Ltd in Uganda.The company has been ranked as amongst the top few fastest growing companies in IndiaORG MargJune 2000. It closed down its manufacturing facility at Saki Naka Andheri Bombay. Globalpharma a joint venture with Dubai Investments Corporation started commercial production in the first quarter of 2002.The company has increased its installed capacity of Liquids by 3.00 lakhs of Litres during 2001 and consequent of this capacity expansion the total installed capacity has gone up to 12.00 lakhs of Litres.The company has also increased its installed capacity of Tablets Capsules by 270 croresNos and the total capacity has gone up to 1080 croresNos.In Feb. 2001 Kopran tied up with EMerck for comarketing a new antiinflammatory drug Rofecoxib in India. Rofecoxib is one of the fastmoving nonsteroid antiinflammatory drugs NSAIDhas been launched in the international market. The Company also launched Cholestat Atorvastatin a cholesterol reducer and further gave comarketing rights for Atorvastatin to EMerck India. The company had launched new products in therapeutic groups like AsthmaCardiologyDiabetes and Lifestyle products during 2003.The company has obtained approval from European Directorate for Quality of MedicinesEDQM in September 2003. Upgradation of Formulation Manufacturing facility took place to meet with the latest International Regulatory Norms.The United Kingdom Medicines and Healthcare Products Regulatory AgencyUK MHRA is expected to inspect the facilities in the first quarter of 2004.
OrganisationKopran Ltd
HeadquartersMumbai
IndustryPharmaceuticals